Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

W. Eikelboom, John; J. Connolly, Stuart; Bosch, Jackie; R. Dagenais, Gilles; G. Hart, Robert; Shestakovska, Olga; Díaz, Rafael; Alings, Marco; Lonn, Eva; S. Anand, Sonia; Widimský, Petr; Hori, Masatsugu; Avezum, Álvaro; Soares Piegas, Leopoldo; R. Branch, Kelley; L. Probstfield, Jeffrey; L. Bhatt, Deepak; Zhu, Jun; Liang, Yan; P. Maggioni, Aldo; López‐Jaramillo, Patricio; O’Donnell, Martin; K. Kakkar, Ajay; A.A. Fox, Keith; Parkhomenko, Alexander; Ertl, Georg; Störk, Stefan; Keltai, Mátyás; Rydén, Lars; Pogosova, Nana; L Dans, Antonio; Laņas, Fernando; Commerford, Patrick; Torp‐Pedersen, Christian; J. Guzik, Tomek; Verhamme, Peter; Vinereanu, Dragoş; Kim, Jae‐Hyung; M. Tonkin, Andrew; S. Lewis, Basil; Félix, Camilo; Yusoff, Khalid; Gabríel Steg, Philippe; Metsärinne, Kaj; Cook Bruns, Nancy; Misselwitz, Frank; Chen, Edmond; P. Leong, Darryl; Yusuf, Salim

doi:10.1056/nejmoa1709118

Public

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

Published in New England Journal of Medicine • Aug 27, 2017

Authors:

John W. Eikelboom

Stuart J. Connolly

Jackie Bosch

Abstract

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive ...

Subject

Rivaroxaban

Aspirin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!